|
| Denosumab (n = 48) | Zoledronic acid (n = 56) |
| Median age (years) | 65.3 (51~79) | 63.1 (55~78) |
| Pathological method |
|
|
| Radical prostatectomy | 10 | 13 |
| Prostatic puncture | 36 | 41 |
| Bone puncture | 2 | 2 |
| Gleason score |
|
|
| 6 | 4 | 6 |
| 7 | 8 | 10 |
| 8 | 8 | 10 |
| 9 | 14 | 14 |
| 10 | 14 | 16 |
| Bone metastasis at first Diagnosis | 30 | 36 |
| Hormone resistance | 18 | 21 |
| Site of bone metastasis |
|
|
| Quadrilateral bone | 12 | 13 |
| Spine | 16 | 19 |
| Multiple bone metastases | 20 | 24 |
| Abnormal renal function | 5 | 6 |
| Spinal cord compression | 5 | 5 |
| Concomitant therapy |
|
|
| Endocrine therapy | 42 | 50 |
| Chemotherapy | 10 | 12 |
| Bone operation | 3 | 2 |
| Radiotherapy |
|
|
| Bone metastasis | 15 | 17 |
| Prostate | 18 | 23 |
| PSA (ug/L) | 18 (6.7~55) | 16 (7~49) |
| Basal bone pain (NRS score) |
|
|
| ≤3 | 33 | 39 |
| 4~6 | 10 | 7 |
| 7~10 | 5 | 7 |
| Median duration of medication (month) | 12 (8~24) | 13 (10~27) |